Amgen Inc.
AMGNNASDAQHealthcare● Active
$349.58
+$3.98(+1.15%)
Market Cap$188.7B
P/E Ratio—
52W High$391.29
52W Low$267.83
Amgen Inc. (AMGN) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
AMGN · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 30, 2026EPS Actual
$5.15
Est. $4.77 · +8.0%
Revenue
$8.62B
Est. $8.58B · +0.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 30, 2026
After Market Close
▲ Beat EPS🔥 7-Quarter EPS Beat Streak
AMGN reports quarterly as a NASDAQ-listed Drug Manufacturers - General company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.84B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.84B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 4, 2026 | $5.55 | — | — | — | $9.43B | — |
| ▲ Q2 FY2026 | Apr 30, 2026 | $4.77 | $5.15 | +8.0% | $8.62B | $8.58B | +0.5% |
| ▲ Q1 FY2026 | Feb 3, 2026 | $4.73 | $5.29 | +11.8% | $9.87B | $9.47B | +4.1% |
| ▲ Q4 FY2025 | Nov 4, 2025 | $5.02 | $5.64 | +12.3% | $9.56B | $8.97B | +6.6% |
| ▲ Q3 FY2025 | Aug 5, 2025 | $5.28 | $6.02 | +14.0% | $9.17B | $8.94B | +2.6% |
| ▲ Q2 FY2025 | May 1, 2025 | $4.27 | $4.90 | +14.8% | $8.15B | $8.06B | +1.1% |
| ▲ Q1 FY2025 | Feb 4, 2025 | $5.04 | $5.31 | +5.4% | $9.09B | $8.88B | +2.3% |
| ▲ Q4 FY2024 | Oct 30, 2024 | $5.11 | $5.58 | +9.2% | $8.50B | $8.50B | +0.1% |
Q3 FY2026
Aug 4, 2026
EPS Actual
—
EPS Est.
$5.55
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 30, 2026Beat
EPS Actual
$5.15
EPS Est.
$4.77
EPS Surpr.
+8.0%
Revenue
$8.62B
Q1 FY2026
Feb 3, 2026Beat
EPS Actual
$5.29
EPS Est.
$4.73
EPS Surpr.
+11.8%
Revenue
$9.87B
Q4 FY2025
Nov 4, 2025Beat
EPS Actual
$5.64
EPS Est.
$5.02
EPS Surpr.
+12.3%
Revenue
$9.56B
Q3 FY2025
Aug 5, 2025Beat
EPS Actual
$6.02
EPS Est.
$5.28
EPS Surpr.
+14.0%
Revenue
$9.17B
Q2 FY2025
May 1, 2025Beat
EPS Actual
$4.90
EPS Est.
$4.27
EPS Surpr.
+14.8%
Revenue
$8.15B
Q1 FY2025
Feb 4, 2025Beat
EPS Actual
$5.31
EPS Est.
$5.04
EPS Surpr.
+5.4%
Revenue
$9.09B
Q4 FY2024
Oct 30, 2024Beat
EPS Actual
$5.58
EPS Est.
$5.11
EPS Surpr.
+9.2%
Revenue
$8.50B
Analyst Estimates
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $5.73 | $5.94 | $6.12 | 10 |
| Q3 FY2028 | $6.02 | $6.24 | $6.43 | 15 |
| Q2 FY2028 | $6.27 | $6.50 | $6.70 | 8 |
| Q1 FY2028 | $5.70 | $5.90 | $6.08 | 11 |
| Q4 FY2027 | $5.98 | $6.20 | $6.39 | 7 |
| Q3 FY2027 | $5.76 | $5.97 | $6.15 | 10 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $9.9B | $10.2B | $10.4B | 6 |
| Q3 FY2028 | $9.7B | $10.0B | $10.2B | 6 |
| Q2 FY2028 | $9.5B | $9.8B | $10.0B | 6 |
| Q1 FY2028 | $9.2B | $9.5B | $9.7B | 6 |
| Q4 FY2027 | $9.9B | $10.2B | $10.4B | 7 |
| Q3 FY2027 | $9.4B | $9.7B | $9.9B | 7 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 30, 2026 | +8.0% | $338.02 | $346.25 | +2.43% |
| ▲ Q1 FY2026 | Feb 3, 2026 | +11.8% | $344.68 | $338.59 | -1.77% |
| ▲ Q4 FY2025 | Nov 4, 2025 | +12.3% | $296.30 | $296.70 | +0.13% |
| ▲ Q3 FY2025 | Aug 5, 2025 | +14.0% | $301.94 | $300.08 | -0.62% |
| ▲ Q2 FY2025 | May 1, 2025 | +14.8% | $290.92 | $283.78 | -2.45% |
| ▲ Q1 FY2025 | Feb 4, 2025 | +5.4% | $288.87 | $289.02 | +0.05% |
| ▲ Q4 FY2024 | Oct 30, 2024 | +9.2% | $316.00 | $315.54 | -0.15% |
| ▲ Q3 FY2024 | Aug 6, 2024 | -0.2% | $325.22 | $328.95 | +1.15% |
Q2 FY2026+2.43%
Report Date
Apr 30, 2026
EPS Beat/Miss
+8.0%
Price Before
$338.02
Price After
$346.25
Q1 FY2026-1.77%
Report Date
Feb 3, 2026
EPS Beat/Miss
+11.8%
Price Before
$344.68
Price After
$338.59
Q4 FY2025+0.13%
Report Date
Nov 4, 2025
EPS Beat/Miss
+12.3%
Price Before
$296.30
Price After
$296.70
Q3 FY2025-0.62%
Report Date
Aug 5, 2025
EPS Beat/Miss
+14.0%
Price Before
$301.94
Price After
$300.08
Q2 FY2025-2.45%
Report Date
May 1, 2025
EPS Beat/Miss
+14.8%
Price Before
$290.92
Price After
$283.78
Q1 FY2025+0.05%
Report Date
Feb 4, 2025
EPS Beat/Miss
+5.4%
Price Before
$288.87
Price After
$289.02
Q4 FY2024-0.15%
Report Date
Oct 30, 2024
EPS Beat/Miss
+9.2%
Price Before
$316.00
Price After
$315.54
Q3 FY2024+1.15%
Report Date
Aug 6, 2024
EPS Beat/Miss
-0.2%
Price Before
$325.22
Price After
$328.95
Avg Beat Reaction-0.15%
Beat Rate8 / 8 quarters
Largest Move-2.45% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: AMGN ends December
Amgen Inc. (AMGN) most recently reported earnings on April 30, 2026 for Q2 FY2026, posting EPS of $5.15 — beating the analyst consensus of $4.77 by +8.0%. AMGN has beaten EPS estimates for 7 consecutive quarters. The next AMGN earnings date is expected around September 1, 2026.
Each quarter, investors track AMGN earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. AMGN revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
AMGN's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
AMGN earnings · 5 questionsAmgen Inc.'s next earnings report is expected around September 1, 2026. AMGN typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; AMGN historically reports after market close (AMC).
AMGN earnings datewhen is AMGN earningsAMGN next earnings datewhen does AMGN report earningsAMGN earnings calendar
▸ Source: FMP · Amgen Inc. SEC filings · US GAAP · Amgen Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026